HOB Biotech Group Corp Ltd (688656) - Total Assets
Based on the latest financial reports, HOB Biotech Group Corp Ltd (688656) holds total assets worth CN¥912.83 Million CNY (≈ $133.58 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check total reinvestment intensity of HOB Biotech Group Corp Ltd to assess the company's total reinvestment commitment from operating cash flow.
HOB Biotech Group Corp Ltd - Total Assets Trend (2016–2025)
This chart illustrates how HOB Biotech Group Corp Ltd's total assets have evolved over time, based on quarterly financial data. Check earnings quality score of HOB Biotech Group Corp Ltd to evaluate the quality of earnings relative to operating cash generation.
HOB Biotech Group Corp Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
HOB Biotech Group Corp Ltd's total assets of CN¥912.83 Million consist of 25.3% current assets and 74.7% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 6.8% |
| Accounts Receivable | CN¥57.00 Million | 6.1% |
| Inventory | CN¥107.08 Million | 11.5% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥11.06 Million | 1.2% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how HOB Biotech Group Corp Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 688656 company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: HOB Biotech Group Corp Ltd's current assets represent 25.3% of total assets in 2025, a decrease from 42.3% in 2016.
- Cash Position: Cash and equivalents constituted 6.8% of total assets in 2025, down from 10.4% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is inventory at 11.5% of total assets.
HOB Biotech Group Corp Ltd Competitors by Total Assets
Key competitors of HOB Biotech Group Corp Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥5.03 Billion |
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
4DMEDICAL Ltd
AU:4DX
|
Australia | AU$139.55 Million |
|
Shanghai MicroPort EV MedTech Co. Ltd. A
SHG:688351
|
China | CN¥2.00 Billion |
|
L&C Bio Co. Ltd
KQ:290650
|
Korea | ₩497.94 Billion |
|
INKON Life Technology Co Ltd
SHE:300143
|
China | CN¥4.17 Billion |
|
Shenzhen Lifotronic Technology Co
SHG:688389
|
China | CN¥2.53 Billion |
|
SS Innovations International Inc. Common Stock
NASDAQ:SSII
|
USA | $90.55 Million |
HOB Biotech Group Corp Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.75 | 1.56 | 3.50 |
| Quick Ratio | 1.40 | 0.88 | 2.44 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥144.91 Million | CN¥94.31 Million | CN¥152.30 Million |
HOB Biotech Group Corp Ltd - Advanced Valuation Insights
This section examines the relationship between HOB Biotech Group Corp Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.44 |
| Latest Market Cap to Assets Ratio | 1.05 |
| Asset Growth Rate (YoY) | -9.8% |
| Total Assets | CN¥931.30 Million |
| Market Capitalization | $979.53 Million USD |
Valuation Analysis
Above Book Valuation: The market values HOB Biotech Group Corp Ltd's assets above their book value (1.05x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: HOB Biotech Group Corp Ltd's assets decreased by 9.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for HOB Biotech Group Corp Ltd (2016–2025)
The table below shows the annual total assets of HOB Biotech Group Corp Ltd from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥931.30 Million ≈ $136.28 Million |
-9.83% |
| 2024-12-31 | CN¥1.03 Billion ≈ $151.13 Million |
+8.80% |
| 2023-12-31 | CN¥949.26 Million ≈ $138.91 Million |
+0.50% |
| 2022-12-31 | CN¥944.56 Million ≈ $138.22 Million |
+9.33% |
| 2021-12-31 | CN¥863.92 Million ≈ $126.42 Million |
+191.46% |
| 2020-12-31 | CN¥296.41 Million ≈ $43.37 Million |
+4.67% |
| 2019-12-31 | CN¥283.18 Million ≈ $41.44 Million |
+25.73% |
| 2018-12-31 | CN¥225.22 Million ≈ $32.96 Million |
+56.16% |
| 2017-12-31 | CN¥144.22 Million ≈ $21.10 Million |
+15.70% |
| 2016-12-31 | CN¥124.65 Million ≈ $18.24 Million |
-- |
About HOB Biotech Group Corp Ltd
HOB Biotech Group Corp.,Ltd. operates as an in vitro diagnostic company in China and internationally. It provides diagnostic tools, such as line immune, enzyme-linked immunosorbent, and chemiluminescent paramagnetic microparticle immune assays to laboratories and hospitals for the improvement of allergy and autoimmune disease patient care. HOB Biotech Group Corp.,Ltd was founded in 2009 and is ba… Read more